The mistake is buying one of them believing it was built for a GLP-1 user's specific physiology, when the design says otherwise
Lebwohl says
A retrospective cohort study, by Dotan et al., involving 318 patients, further revealed that treatment with GLP-1 RAs was associated with a reduced risk of major adverse cardiovascular events (MACEs) and all-cause mortality among solid organ transplant recipients, including kidney, lung, liver, and heart transplants [23]
Using a GLP-1 medication? Meet your GLP-1 ally
This is changing as GLP-1 awareness grows, but uptake remains uneven based on clinical training, time constraints, and confidence managing long-term injectable therapy or metabolic side effects
It has the potential to speed up the recovery of musculoskeletal injuries but is not yet approved by the FDA for clinical use in humans